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ABSTRACT
As part of the tigecycline evaluation and surveillance trial (TEST), bacterial isolates were collected from
39 centres in France, Germany, Italy, Spain and the UK between January 2004 and August 2006.
Antimicrobial susceptibilities were determined according to CLSI guidelines. Italy had the highest rate
of methicillin-resistant Staphylococcus aureus (36.4%), and was the only country to report vancomycin-
resistant Enterococcus faecalis (8.6%). Tigecycline was the only agent to which all Gram-positive isolates
were susceptible. For many of the Gram-negative organisms collected, antimicrobial susceptibilities
were lowest among isolates from Italy and highest among isolates from Spain. The notable exception
was Acinetobacter baumannii, where the poorest susceptibility proﬁle was among isolates from Spain. For
A. baumannii, MIC90s of imipenem varied from 1 mg ⁄L for isolates in France and Germany to ‡32 mg ⁄L
for isolates from Italy and Spain. Tigecycline was the only agent to maintain an MIC90 of £1 mg ⁄L
against isolates from all ﬁve countries. The in-vitro activity of tigecycline against both Gram-positive
and Gram-negative isolates may make it valuable in the treatment of hospital infections, including those
caused by otherwise antimicrobial-resistant organisms.
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INTRODUCTION
Resistant Gram-positive organisms, e.g., methicil-
lin-resistant Staphylococcus aureus (MRSA), con-
tinue to pose challenges for appropriate
treatment, and resistant Gram-negative organ-
isms, e.g., Acinetobacter baumannii, have also
emerged as problematic pathogens. Against a
background of antimicrobial resistance and a
reduction in the rate of development of new
antimicrobial agents [1], tigecycline, a novel
glycylcycline, was approved for use in Europe
in 2006 for complicated skin and soft-tissue and
intra-abdominal infections (http://www.emea.
europa.eu/humandocs/Humans/EPAR/tygacil/
tygacil.htm). Tigecycline is a broad-spectrum
antimicrobial agent that was developed to over-
come two key tetracycline resistance mechanisms
(efﬂux pump and ribosomal protection) [2]; it
is also unaffected by other resistance mecha-
nisms, including extended-spectrum b-lactamases
(ESBLs) [3,4].
The tigecycline evaluation and surveillance
trial (TEST) began in 2004, with the aim of
assessing the in-vitro activity of tigecycline and
comparator compounds against a wide variety
of organisms, and involves 272 centres in 34
countries worldwide. The present report provides
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in-vitro susceptibility data for Gram-positive and
Gram-negative bacterial isolates collected be-
tween 2004 and 2006 from France, Germany,
Italy, Spain and the UK.
MATERIALS AND METHODS
Collection of isolates
Between January 2004 and August 2006, isolates were collected
from nine medical centres in France, seven in Germany, 11 in
Italy, eight in Spain and four in the UK as part of the TEST
surveillance study. All centres were large teaching institutions
and were selected on the basis of demographical and geo-
graphical diversity.
Isolates were collected from both inpatients and outpa-
tients with a documented infection in which the isolate
collected was identiﬁed as the probable causative organism
according to institutional criteria. Accepted collection sources
were blood, respiratory tract samples, urine (not exceeding
25% of isolates from any one centre), skin samples, wound
specimens, ﬂuids and other deﬁned sources. Only one isolate
per patient was included in the study. Inclusion was
independent of medical history, antimicrobial use, age and
gender. Banked, stored or duplicate isolates were excluded
from the study. Isolates were consecutive and the participat-
ing centres were requested to submit 25 Staph. aureus, 15
Enterococcus spp., ten Streptococcus agalactiae, 15 Acinetobacter
spp., 25 Klebsiella spp., 25 Escherichia coli, 20 Pseudomonas
aeruginosa and 25 Enterobacter spp.
A single reference laboratory, Laboratories International for
Microbiology Studies (a division of International Health
Management Associates (IHMA); Schaumburg, IL, USA),
coordinated all efforts with respect to collection of isolates,
transport, conﬁrmation of identiﬁcations, and development
and management of a central database. All isolates included in
the database were within quality control limits; in addition,
quality control checks were carried out on c. 10% of the
isolates.
Antimicrobial susceptibility testing
As deﬁned by the TEST protocol, MICs were determined at
each medical centre using CLSI broth microdilution method-
ology [5] in conjunction with either MicroScan panels (Dade
Microscan Inc., West Sacremento, CA, USA) or Sensititre plates
(TREK Diagnostic Systems, East Grinstead, UK). The panel of
agents tested against Gram-positive organisms was: penicillin,
ampicillin, amoxycillin–clavulanate, piperacillin–tazobactam,
ceftriaxone, imipenem (MicroScan only), levoﬂoxacin, linezo-
lid, vancomycin, minocycline and tigecycline. The panel of
antimicrobial agents tested against Gram-negative organisms
was: ampicillin, amoxycillin–clavulanate, piperacillin–tazobac-
tam, ceftriaxone, ceftazidime, cefepime, imipenem (MicroScan
only), amikacin, levoﬂoxacin, minocycline and tigecycline.
Quality control testing was performed on each day of testing
using E. coli ATCC 25922 and ATCC 35218, Staph. aureus
ATCC 29213, P. aeruginosa ATCC 27853, Enterococcus faecalis
ATCC 29212 and Streptococcus pneumoniae ATCC 49619, as
appropriate. Susceptibility was determined according to CLSI
interpretive criteria [6], with the exception of tigecycline, for
which EUCAST interpretive criteria were applied [7] (http://
www.srga.org/eucastwt/MICTAB/index.html).
Antimicrobial resistance determinations
Methicillin resistance among Staph. aureus isolates was
detected using local methodology, and was then conﬁrmed
at the central laboratory using the cefoxitin disk-diffusion
method (30-lg disks; Remel, Lenexa, KS, USA). Klebsiella
pneumoniae and E. coli were analysed for the presence
of ESBLs according to CLSI methodology [6]. The disks
used were cefotaxime (30 lg), cefotaxime–clavulanic acid
(30 ⁄ 10 lg), ceftazidime (30 lg), and ceftazidime–clavulanic
acid (30 ⁄ 10 lg). Disks were manufactured by Oxoid
(Ogdensburg, NY, USA) and the Mueller–Hinton agar used
for testing was obtained from Remel. A positive ESBL result
was indicated by an increase of ‡5 mm in the inhibition zone
around the combination disk in comparison with the ceph-
alosporin disk alone. Quality control strains used were
K. pneumoniae ATCC 700603, E. coli ATCC 25922 and
P. aeruginosa ATCC 27853.
RESULTS
Gram-positive organisms
The numbers of Staph. aureus, Ent. faecalis, Entero-
coccus faecium and Strep. agalactiae isolates col-
lected as part of TEST between January 2004 and
August 2006 in France, Germany, Italy, Spain and
the UK are shown in Table 1. Overall, 67.2% of
these isolates were collected from inpatients
and 16.6% were from outpatients (with source
unknown for 16.2% of isolates); 66.6% were from
non-intensive care unit (ICU) patients, 17.3%
were from ICU patients (16.1% were source
unknown), and 51.5% were isolates from male
patients (0.5% were source unknown).
The highest percentage of MRSA (36.4%) was
detected in isolates from Italy (Table 2). Linezolid,
Table 1. Total numbers of Gram-positive and Gram-neg-
ative organisms collected between January 2004 and
August 2006 from France, Germany, Italy, Spain and the
UK (number of isolates tested against imipenem are shown
in parentheses)
Organism France Germany Italy Spain UK
Staphylococcus aureus 187 (172) 180 (180) 209 (207) 191 (191) 97 (97)
Enterococcus faecalis 101 (97) 84 (84) 105 (102) 94 (94) 37 (35)
Enterococcus faecium 24 (24) 30 (29) 49 (48) 22 (22) 16 (16)
Streptococcus agalactiae 76 (70) 74 (64) 85 (77) 59 (59) 38 (38)
Klebsiella pneumoniae 148 (148) 120 (120) 207 (203) 138 (136) 65 (61)
Escherichia coli 225 (224) 195 (195) 275 (274) 201 (201) 99 (99)
Enterobacter spp. 220 (217) 196 (196) 261 (257) 181 (177) 89 (84)
Acinetobacter baumannii 113 (113) 86 (86) 98 (98) 97 (97) 42 (42)
Pseudomonas aeruginosa 178 (178) 156 (155) 207 (204) 160 (160) 79 (79)
308 Clinical Microbiology and Infection, Volume 14 Number 4, April 2008
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 307–314
tigecycline and vancomycin were the only agents
to which all MRSA isolates were susceptible
(Table 3). All methicillin-susceptible Staph. aureus
isolates, irrespective of their country of origin,
were susceptible to amoxycillin–clavulanate,
imipenem, linezolid, piperacillin–tazobactam,
tigecycline and vancomycin. The largest varia-
tions in susceptibility among the ﬁve countries
were between Italy and Spain for penicillin
(31.6% and 4.6%, respectively) (Table 3). MIC90s
did not vary among the ﬁve countries by more
than one doubling-dilution of any of the antimi-
crobial agents tested.
Isolates of Ent. faecalis collected from all ﬁve
countries were susceptible to ampicillin, penicillin
Table 2. Distribution of methicillin-resistant Staphylococ-
cus aureus (MRSA), vancomycin-resistant enterococci,
extended-spectrum b-lactamase (ESBL)-producing Klebsi-
ella pneumoniae and ESBL-producing Escherichia coli col-
lected between January 2004 and August 2006 from France,
Germany, Italy, Spain and the UK
Organism
France Germany Italy Spain UK
n % n % n % n % n %
MRSA 53 28.3 36 20.0 76 36.4 39 20.4 21 21.6
Vancomycin-resistant
Enterococcus faecalis
0 0.0 0 0.0 9 8.6 0 0.0 0 0.0
Vancomycin-resistant
Enterococcus faecium
0 0.0 2 6.7 10 20.4 0 0.0 5 31.3
ESBL-producing
K. pneumoniae
14 9.5 8 6.7 47 22.7 9 6.5 16 24.6
ESBL-producing
E. coli
11 4.9 9 4.6 34 12.4 4 2.0 12 12.1
Table 3. In-vitro activity (MIC90, mg ⁄L) and susceptibility of Gram-positive organisms collected between January 2004
and August 2006 from France, Germany, Italy, Spain and the UK
Organism ⁄ antimicrobial
agent
France Germany Italy Spain UK Susceptible
breakpoint
mg ⁄L%S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90
Methicillin-resistant Staphylococcus aureus
Levoﬂoxacin 9.4 32 0.0 16 7.9 ‡64 7.7 16 4.8 16 1
Linezolid 100 2 100 4 100 4 100 2 100 4 4
Vancomycin 100 1 100 1 100 2 100 1 100 1 2
Minocycline 94.3 4 100 0.5 100 2 100 0.5 95.2 0.5 4
Tigecycline 100 0.25 100 0.25 100 0.25 100 0.25 100 0.25 0.5a
Methicillin-susceptible Staphylococcus aureus
Penicillin 20.1 ‡16 23.6 ‡16 31.6 ‡16 4.6 ‡16 13.2 ‡16 0.12
Amoxy-clav 100 1 100 2 100 1 100 2 100 1 4
Pip-tazo 100 1 100 1 100 2 100 1 100 1 8
Ceftriaxone 100 4 100 4 99.2 4 99.3 4 98.7 4 8
Imipenem 100 0.5 100 0.5 100 0.25 100 0.25 100 0.25 4
Levoﬂoxacin 97.8 0.25 98.6 0.5 96.2 0.5 98.7 0.25 100 0.25 1
Linezolid 100 4 100 4 100 4 100 2 100 4 4
Vancomycin 100 1 100 1 100 1 100 1 100 1 2
Minocycline 97.0 £0.25 100 £0.25 100 £0.25 100 £0.25 100 0.5 4
Tigecycline 100 0.12 100 0.25 100 0.25 100 0.12 100 0.25 0.5a
Enterococcus faecalis
Ampicillin 100 1 100 2 100 2 100 2 100 1 8
Imipenem – 2 – 4 – 4 – 2 – 2 –
Levoﬂoxacin 94.1 1 53.6 ‡64 67.6 32 64.9 32 35.1 ‡64 2
Linezolid 93.1 2 95.2 2 97.1 2 97.9 2 100 2 2
Vancomycin 100 2 100 2 91.4 4 100 2 100 2 4
Minocycline 33.7 ‡16 26.2 ‡16 33.3 ‡16 50.0 ‡16 37.8 ‡16 4
Tigecycline 100 0.25 100 0.25 100 0.25 100 0.12 100 0.12 0.25a
Enterococcus faecium
Ampicillin 41.7 ‡32 3.3 ‡32 32.7 ‡32 27.3 ‡32 31.3 ‡32 8
Imipenem – ‡32 – ‡32 – ‡32 – ‡32 – ‡32 –
Levoﬂoxacin 50.0 ‡64 10.0 ‡64 28.6 ‡64 45.5 ‡64 6.3 ‡64 2
Linezolid 75.0 4 93.3 2 91.8 2 100 2 93.8 2 2
Vancomycin 100 1 93.3 1 75.5 ‡64 100 1 68.8 ‡64 4
Minocycline 54.2 ‡16 83.3 ‡16 73.5 ‡16 77.3 ‡16 68.8 8 4
Tigecycline 100 0.12 100 0.12 100 0.12 100 0.12 100 0.12 0.25a
Streptococcus agalactiae
Penicillin 100 0.12 100 0.12 100 0.12 100 £0.06 100 0.12 0.25
Ampicillin 100 0.12 100 0.12 100 0.12 100 0.12 100 0.12 0.25
Ceftriaxone 100 0.12 100 0.12 100 0.12 100 0.06 100 0.12 0.5
Imipenem – 0.25 – 0.5 – 0.25 – 0.5 – 0.5 –
Levoﬂoxacin 100 1 100 1 100 1 100 1 100 1 2
Linezolid 100 1 100 1 100 1 100 1 100 1 2
Vancomycin 100 0.5 100 0.5 100 0.5 100 0.5 100 0.5 1
Minocycline 27.6 ‡16 25.7 ‡16 21.2 ‡16 25.4 ‡16 23.7 ‡16 2
Tigecycline 100 0.25 100 0.25 100 0.06 100 0.06 100 0.25 0.25a
aEUCAST interpretive criteria [7] applied for tigecycline where available.
amoxy-clav, amoxycillin–clavulanate; pip-tazo, piperacillin–tazobactam; %S, percentage susceptible.
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and tigecycline (Table 3). All isolates from France,
Germany, Spain and the UK were also susceptible
to vancomycin. Nine (8.6%) isolates from Italy
were vancomycin-resistant. A large variation in
the percentage of Ent. faecalis isolates susceptible
to levoﬂoxacin was noted, from 94.1% in France
to 35.1% in the UK. MIC90s of levoﬂoxacin also
varied, from 1 mg ⁄L for isolates from France to
‡64 mg ⁄L for isolates from Germany and the UK.
Small numbers of Ent. faecium isolates were
collected from all ﬁve European countries (Ta-
ble 1), with vancomycin-resistant isolates being
detected in Germany (6.7%), Italy (20.4%) and the
UK (31.3%). Antimicrobial susceptibility varied
among the ﬁve European countries (Table 3).
MIC90s of the majority of agents were high; the
most active agents were linezolid (2–4 mg ⁄L) and
tigecycline (0.12 mg ⁄L). Vancomycin maintained
activity in France, Germany and Spain (MIC90
1 mg ⁄L). Tigecycline was the only agent to which
all isolates of Ent. faecium were susceptible. Lin-
ezolid was also highly active and no resistant
isolates were detected.
The majority of agents in the test panel were
active against Strep. agalactiae, irrespective of the
country of origin (Table 3).
Gram-negative organisms
Table 1 shows the number of isolates of K. pneu-
moniae, E. coli, Enterobacter spp., A. baumannii and
P. aeruginosa collected from France, Germany,
Italy, Spain and the UK as part of TEST between
January 2004 and August 2006. In total, 72.4% of
these isolates were from inpatients and 13.4%
were from outpatients (with source unknown for
14.2% of isolates); 57.6% were from male patients
(0.5% were source unknown) and 59.7% were
from non-ICU patients (26.9% were from ICU
patients, 14.2% were source unknown).
For K. pneumoniae, susceptibility and in-vitro
activity were variable among the ﬁve countries,
with susceptibility rates being notably lower for
many of the agents for isolates collected from
Italy, and the highest rates of susceptibility being
generally noted for isolates from Spain. Levoﬂox-
acin MIC90s varied from 0.5 mg ⁄L in Spain to
‡16 mg ⁄L in Italy and the UK, while ceftriaxone
MIC90s varied from 2 mg ⁄L in Spain to
‡128 mg ⁄L in Italy and the UK (Table 4). The
highest rates of ESBL-producing isolates were
found in Italy and the UK (Table 2), and ceftaz-
idime susceptibility was also lowest for isolates
from these two countries. There was 100% sus-
ceptibility to imipenem for isolates from all ﬁve
countries.
As with K. pneumoniae, in-vitro activity against
E. coli was variable among the ﬁve countries, e.g.,
MIC90s of ceftriaxone varied from 0.25 mg ⁄L in
France and Germany to 64 mg ⁄L in Italy. The
percentage of isolates identiﬁed as ESBL produc-
ers was highest in Italy and the UK (Table 2). All
isolates from all ﬁve countries were susceptible to
imipenem. All isolates from Germany, Italy, Spain
and the UK were susceptible to tigecycline. In
France, all isolates were susceptible, with the
exception of one isolate that was intermediate for
tigecycline (MIC, 2 mg ⁄L) (Table 4).
For piperacillin–tazobactam, ceftazidime, cef-
triaxone, cefepime, amikacin, minocycline and
tigecycline, the highest rates of susceptibility for
Enterobacter spp. were found in Spain (Table 4).
For many of the agents tested, the lowest rates of
susceptibility were noted in Italy. All isolates
were susceptible to imipenem, irrespective of the
country of origin. The most active agents were
imipenem (1 mg ⁄L) and tigecycline (1–2 mg ⁄L).
Levoﬂoxacin MIC90s varied from 0.12 mg ⁄L in
Spain to ‡16 mg ⁄L in France and Italy.
Few agents in the TEST panel were active
against A. baumannii. Tigecycline was the only
agent to maintain an MIC90 of £1 mg ⁄L across all
ﬁve countries (Table 4). MIC90s of imipenem
varied from 1 mg ⁄L for isolates from France and
Germany to ‡32 mg ⁄L for isolates from Italy and
Spain. Isolates from Spain had the lowest suscep-
tibilities for all antimicrobial agents in the panel
(where susceptibility data were available), with
susceptibility ranging from 14.4% for ceftriaxone
to 59.8% for minocycline. Isolates from Germany
had the best susceptibility proﬁle, with suscepti-
bilities of >80% for amikacin, cefepime, ceftazi-
dime, imipenem, levoﬂoxacin, minocycline and
piperacillin–tazobactam.
Susceptibilities of the P. aeruginosa isolates col-
lected were lowest for isolates collected from
Italy, and highest, for the majority of agents,
for isolates from the UK. Amikacin and
imipenem were the most active agents, with
MIC90s of 8–32 mg ⁄L and 8–16 mg ⁄L, respec-
tively. Amikacin had the highest rates of suscep-
tibility (>96% for isolates from France, Germany,
Spain and the UK) (Table 4). Susceptibilities to
piperacillin–tazobactam were also high, with
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>91% of isolates collected from Germany, Spain
or the UK being susceptible. MIC90s were
‡8 mg ⁄L for all antimicrobial–country combina-
tions.
DISCUSSION
The results of this study conﬁrmed the broad-
spectrum activity of tigecycline against a range of
Gram-positive and Gram-negative organisms col-
lected from France, Germany, Italy, Spain and the
UK. Tigecycline, linezolid and vancomycin were
the only agents that were active against all MRSA
isolates from all ﬁve countries. The activity of
tigecycline against MRSA, as reported by TEST, is
similar to that reported previously from European
and global studies (MIC90s, 0.25–0.5 mg ⁄L) [8–10],
and that for MRSA isolates collected from patients
with skin and skin-structure and intra-abdominal
infections in phase 3 clinical trials (MIC90,
0.25 mg ⁄L) [11]. All ﬁve countries had rates of
MRSA of >20%, which agree broadly with those
Table 4. In-vitro activity (MIC90, mg ⁄L) and susceptibility of Gram-negative organisms collected between January 2004
and August 2006 from France, Germany, Italy, Spain and the UK
Organism ⁄ antimicrobial
agent
France Germany Italy Spain UK Susceptible
breakpoint
mg ⁄L%S MIC90 %S MIC90 %S MIC90 %S MIC90 %S MIC90
Klebsiella pneumoniae
Amoxy-clav 81.1 16 79.2 32 63.3 32 84.8 16 75.4 32 8
Pip-tazo 94.6 8 94.2 8 75.8 128 92.8 8 93.8 16 16
Ceftriaxone 91.2 4 88.3 32 75.4 ‡128 94.2 2 78.5 ‡128 8
Ceftazidime 89.9 16 89.2 16 65.2 ‡64 94.2 £8 81.5 ‡64 8
Cefepime 93.2 1 94.2 4 83.6 32 94.9 1 87.7 16 8
Imipenem 100 0.5 100 0.5 100 0.5 100 0.5 100 0.5 4
Amikacin 97.3 4 100 2 90.3 16 99.3 4 100 4 16
Levoﬂoxacin 90.5 2 90.0 2 80.2 ‡16 96.4 0.5 76.9 ‡16 2
Minocycline 75.0 ‡32 67.5 16 76.8 16 86.2 8 75.4 16 4
Tigecycline 87.8 2 79.2 4 91.3 1 97.1 1 83.1 2 1a
Escherichia coli
Ampicillin 49.8 ‡64 49.2 ‡64 39.3 ‡64 21.4 ‡64 38.4 ‡64 8
Amoxy-clav 76.9 32 74.9 32 64.0 32 62.7 32 77.8 16 8
Pip-tazo 92.4 8 99.0 4 89.1 32 92.0 16 96.0 8 16
Ceftriaxone 94.7 0.25 94.4 0.25 85.8 64 91.5 2 80.8 ‡128 8
Ceftazidime 96.0 £8 97.9 £8 87.3 32 96.0 £8 92.9 £8 8
Cefepime 95.1 £0.5 95.4 £0.5 90.5 8 98.0 2 90.9 8 8
Imipenem 100 0.5 100 0.5 100 0.5 100 0.5 100 0.5 4
Amikacin 99.6 8 100 4 99.3 8 100 4 99.0 4 16
Levoﬂoxacin 84.9 8 84.1 8 67.3 ‡16 71.6 8 68.7 ‡16 2
Minocycline 85.8 8 80.0 8 77.5 16 86.1 8 83.8 8 4
Tigecycline 99.6 0.25 100 0.25 100 0.5 100 0.25 100 0.25 1a
Enterobacter spp.
Pip-tazo 64.5 128 75.0 128 59.0 128 82.9 32 80.9 64 16
Ceftriaxone 62.3 ‡128 73.5 64 52.9 ‡128 83.4 16 62.9 64 8
Ceftazidime 54.1 ‡64 68.4 ‡64 42.9 ‡64 76.2 32 61.8 ‡64 8
Cefepime 87.7 16 98.5 4 86.2 16 98.9 1 94.4 8 8
Imipenem 100 1 100 1 100 1 100 1 100 1 4
Amikacin 97.7 8 99.5 4 95.8 16 100 2 98.9 4 16
Levoﬂoxacin 71.8 ‡16 95.9 1 68.2 ‡16 97.8 0.12 87.6 4 2
Minocycline 72.3 8 83.7 8 79.7 8 98.3 4 83.1 8 4
Tigecycline 82.3 2 88.3 2 88.1 2 97.8 1 91.0 1 1a
Acinetobacter baumannii
Pip-tazo 77.0 64 86.0 64 58.2 128 32.0 128 54.8 128 16
Ceftriaxone 40.7 ‡128 58.1 64 29.6 ‡128 14.4 ‡128 33.3 ‡128 8
Ceftazidime 70.8 ‡64 82.6 32 41.8 ‡64 24.7 ‡64 50.0 ‡64 8
Cefepime 68.1 32 83.7 16 38.8 ‡64 29.9 32 52.4 ‡64 8
Imipenem 98.2 1 97.7 1 83.7 ‡32 61.9 ‡32 83.3 16 4
Amikacin 87.6 32 93.0 4 62.2 ‡128 52.6 ‡128 85.7 ‡128 16
Levoﬂoxacin 61.9 8 86.0 8 50.0 ‡16 24.7 ‡16 54.8 ‡16 2
Minocycline 99.1 2 97.7 £0.5 99.0 2 59.8 16 88.1 8 4
Tigecycline – 0.5 – 0.5 – 1 – 1 – 1 –a
Pseudomonas aeruginosa
Pip-tazo 89.3 128 95.5 64 82.6 128 91.3 64 92.4 64 64
Ceftazidime 84.8 32 84.6 16 64.3 ‡64 76.3 16 86.1 32 8
Cefepime 79.8 32 83.3 16 57.0 ‡64 83.8 16 87.3 32 8
Imipenem 86.5 8 80.6 8 77.0 16 81.3 8 88.6 8 4
Amikacin 96.1 8 98.1 8 88.9 32 96.9 8 96.2 8 16
Levoﬂoxacin 64.0 ‡16 72.4 ‡16 52.2 ‡16 71.3 ‡16 75.9 ‡16 2
Minocycline 3.4 ‡32 7.7 ‡32 3.4 ‡32 3.1 ‡32 10.1 ‡32 4
Tigecycline – 16 – 16 – ‡32 – ‡32 – 16 –a
aEUCAST interpretive criteria [7] applied for tigecycline where available.
Amoxy-clav, amoxycillin–clavulanate; pip-tazo, piperacillin–tazobactam; %S, percentage susceptible.
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reported by the European Antimicrobial Resis-
tance Surveillance System for invasive isolates
(http://www.rivm.nl/earss/). One exception
was the percentage of Staph. aureus isolates that
were identiﬁed as MRSA in the UK; this was
21.6% in TEST and 44.0% in EARSS (http://
www.rivm.nl/earss/). The UK is known to have a
high rate of MRSA, although the rate varies
among hospitals and patient groups [12]. Re-
cently, the proportion of Staph. aureus identiﬁed
as methicillin-resistant in the UK appears to have
stabilised (http://www.rivm.nl/earss/), and the
lower number of MRSA isolates detected in TEST
may be related to the relatively low number of
Staph. aureus isolates (n = 97) submitted by the
four UK sites.
As with MRSA, the in-vitro activity of tigecy-
cline against both Ent. faecalis and Ent. faecium
was similar to that reported by other European
studies and that for isolates collected from
phase 3 clinical trial patients (MIC90s,
£0.25 mg ⁄L) [8,9,11]. Tigecycline was the only
agent to which all Ent. faecium isolates were
susceptible, irrespective of their country of origin.
Linezolid was also highly active, with no resistant
isolates reported. However, low numbers of
Ent. faecalis isolates with a linezolid MIC of
4 mg ⁄L (intermediate according to CLSI guide-
lines) were detected in France, Germany, Italy
and Spain, and low numbers of Ent. faecium were
detected in France, Germany, Italy and the UK.
Such isolates have been reported by other studies
in Europe [13,14] and highlight the importance of
continued surveillance. Vancomycin-resistant iso-
lates of Ent. faecalis were found among isolates
from Italy, and both Italy and the UK reported
vancomycin resistance rates of >20% among
isolates of Ent. faecium. High incidences of vanco-
mycin-resistant enterococci have been reported
previously for the UK and Italy [15–18], with rates
as high as 60.6% for vancomycin-resistant
Ent. faecium from Italy [15]. Goossens et al. [17]
suggested that the high rates could be related to
the monoclonal emergence and spread of centre-
speciﬁc clones.
Among the Gram-negative isolates tested, tige-
cycline was highly active against members of the
Enterobacteriaceae, with MIC90s ranging from
0.25 for E. coli (France, Germany, Spain and the
UK) to 4 mg ⁄L for K. pneumoniae (Germany).
Similar levels of tigecycline activity against E. coli
and Enterobacter spp. have been reported previ-
ously, with MIC90s of 0.5–1 and 1–2 mg ⁄L,
respectively [8–11]. For K. pneumoniae, the MIC90
of 4 mg ⁄L for Germany was higher than that for
other countries, although the MIC50 (0.5 mg ⁄L)
was the same as that reported for France, Italy
and the UK. Low numbers of isolates of K. pneu-
moniae with tigecycline MICs ‡4 mg ⁄L have been
reported previously in Europe [4,19].
Acinetobacter baumannii is a problematic patho-
gen, particularly in ICUs. The results from TEST
reveal that no antimicrobial agent tested was
active against all isolates of A. baumannii col-
lected, irrespective of the country of origin.
Tigecycline was the only agent that maintained
an MIC90 of £1 mg ⁄L for isolates from all ﬁve
countries. These results are in accord with previ-
ously published studies of global and European
isolates, with MIC90s ranging from 1 to 2 mg ⁄L
for A. baumannii and Acinetobacter spp.
[8,10,11,20]. Until recently, the carbapenems were
considered to be a viable treatment option for
Acinetobacter spp., but the situation has changed
with the emergence of carbapenem-resistant
Acinetobacter spp., and in-vitro susceptibility to
imipenem in TEST was <90% in Italy, Spain and
the UK. Similar rates of susceptibility have been
reported previously [21,22], and such resistance
has led to a resurgence of interest in older
antimicrobial agents such as colistin [23]. In a
report on the occurrence of carbapenem-resistant
A. baumannii in London and the south-east of
England, Coelho et al. [24] described two multi-
resistant clones, with one being susceptible only
to tigecycline and colistin, and the second being
susceptible only to tigecycline, colistin, amikacin
and minocycline.
P. aeruginosa is an opportunistic pathogen that
is particularly problematic among critically-ill
patients. As demonstrated by the TEST data,
there are few agents available with full activity,
and tigecycline is not clinically effective against
P. aeruginosa [8]. The highest rates of susceptibil-
ity were for imipenem, piperacillin–tazobactam
and amikacin, and, as with other organisms in
this study, isolates from Italy had the lowest
susceptibility proﬁle. The activity of imipenem,
piperacillin–tazobactam and amikacin is sup-
ported by previous surveillance studies [21,25,26].
This analysis of the TEST data has demon-
strated the continuing variability in antimicrobial
susceptibilities among Gram-positive and Gram-
negative organisms within Europe. In particular,
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many of the Gram-positive and Gram-negative
organisms from Italy had notably low suscepti-
bility proﬁles. Tigecycline was shown to have
excellent activity against isolates of Staph. aureus,
Ent. faecalis, Ent. faecium, Strep. agalactiae, E. coli
and A. baumannii. Tigecycline also had good
activity against K. pneumoniae and Enterobacter
spp., and may be a useful option for the treatment
of skin and soft-tissue and intra-abdominal infec-
tions.
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